Literature DB >> 21095315

Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer.

Brendon M Stiles1, Farooq Mirza, Jeffrey L Port, Paul C Lee, Subroto Paul, Paul Christos, Nasser K Altorki.   

Abstract

BACKGROUND: Although patients with esophageal cancer (EC) often develop lymph node metastases in the cervical and recurrent laryngeal (CRL) distribution, lymphadenectomy in this field is rarely performed. The purpose of this study was to determine factors associated with CRL node positivity and to determine the appropriate indications to perform a "three field" lymphadenectomy.
METHODS: In a retrospective review, EC patients who underwent three-field lymphadenectomy were analyzed. Predictors of positive CRL nodes were examined univariately, then selected for inclusion in a multivariate logistic regression model.
RESULTS: From 1994 to 2009, 185 patients had a three-field lymphadenectomy, of whom 46 patients (24.9%) had positive CRL nodes. Final pathology stages (seventh edition) were I in 24 patients, II in 43, III in 109, and IV in 1 patient. Eight patients had a major pathologic response after induction therapy. On univariate analysis, variables significantly associated with positive CRL nodes included squamous cell histology, proximal location, advanced clinical presentation, the presence of clinical nodal disease, higher pT classification, and higher pN classification. There was no reduction in the rate of positive CRL nodes after induction chemotherapy. On multivariate analysis, higher pN classification (adjusted odds ratio 16.25, 95% confidence interval: 5.40 to 48.87; p < 0.0001) and squamous histology (adjusted odds ratio 6.04, 95% confidence interval: 2.21 to 16.56; p < 0.0001) predicted positive CRL nodes.
CONCLUSIONS: Complete lymphadenectomy is necessary in esophageal cancer to appropriately stage patients. Low rates of positive CRL nodes are present with early clinical stage, with pT0-2 tumors, and with pN0 classification, particularly in patients with adenocarcinoma and gastroesophageal junction tumors. Dissection of the CRL field should be considered with advanced disease for adenocarcinoma and in all patients with squamous cell cancer.
Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21095315     DOI: 10.1016/j.athoracsur.2010.06.085

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Three-field lymph node dissection in treating the esophageal cancer.

Authors:  Qi-Xin Shang; Long-Qi Chen; Wei-Peng Hu; Han-Yu Deng; Yong Yuan; Jie Cai
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Extensive mediastinal lymphadenectomy during minimally invasive esophagectomy: optimal results from a single center.

Authors:  Yaxing Shen; Yi Zhang; Lijie Tan; Mingxiang Feng; Hao Wang; Muhammad Asim Khan; Mingqiang Liang; Qun Wang
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

3.  Retrospective study using the propensity score to clarify the oncologic feasibility of thoracoscopic esophagectomy in patients with esophageal cancer.

Authors:  Shinsuke Takeno; Yoshiaki Takahashi; Toshihiko Moroga; Katsunobu Kawahara; Yuichi Yamashita; Megu Ohtaki
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

4.  High Intrathoracic Anastomosis with Thoracoscopy Is Safe and Feasible for Treatment of Esophageal Squamous Cell Carcinoma.

Authors:  Hyun Woo Jeon; Jae Kil Park; Kyo Young Song; Sook Whan Sung
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

5.  Patterns of lymph node recurrence after radical surgery impacting on survival of patients with pT1-3N0M0 thoracic esophageal squamous cell carcinoma.

Authors:  Xiao-Li Chen; Tian-Wu Chen; Zhi-Jia Fang; Xiao-Ming Zhang; Zhen-Lin Li; Hang Li; Hong-Jie Tang; Li Zhou; Dan Wang; Zishu Zhang
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.